A sugar phosphatase regulates the methylerythritol phosphate (MEP) pathway in malaria parasites by Guggisberg, Ann M et al.




A sugar phosphatase regulates the methylerythritol
phosphate (MEP) pathway in malaria parasites
Ann M. Guggisberg
Washington University School of Medicine in St. Louis
Jooyoung Park
Washington University School of Medicine in St. Louis
Rachel L. Edwards
Washington University School of Medicine in St. Louis
Megan L. Kelly
Washington University School of Medicine in St. Louis
Dana M. Hodge
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Guggisberg, Ann M.; Park, Jooyoung; Edwards, Rachel L.; Kelly, Megan L.; Hodge, Dana M.; Tolia, Niraj H.; and Odom, Audrey R.,




Ann M. Guggisberg, Jooyoung Park, Rachel L. Edwards, Megan L. Kelly, Dana M. Hodge, Niraj H. Tolia, and
Audrey R. Odom
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/4292
ARTICLE
Received 6 Dec 2013 | Accepted 20 Jun 2014 | Published 24 Jul 2014
A sugar phosphatase regulates the methylerythritol
phosphate (MEP) pathway in malaria parasites
Ann M. Guggisberg1,*, Jooyoung Park2,*, Rachel L. Edwards1, Megan L. Kelly1, Dana M. Hodge1,
Niraj H. Tolia2,3,y & Audrey R. Odom1,2,y
Isoprenoid biosynthesis through the methylerythritol phosphate (MEP) pathway generates
commercially important products and is a target for antimicrobial drug development. MEP
pathway regulation is poorly understood in microorganisms. Here we employ a forward
genetics approach to understand MEP pathway regulation in the malaria parasite, Plasmodium
falciparum. The antimalarial fosmidomycin inhibits the MEP pathway enzyme deoxyxylulose
5-phosphate reductoisomerase (DXR). Fosmidomycin-resistant P. falciparum are enriched for
changes in the PF3D7_1033400 locus (hereafter referred to as PfHAD1), encoding a homo-
logue of haloacid dehalogenase (HAD)-like sugar phosphatases. We describe the structural
basis for loss-of-function PfHAD1 alleles and ﬁnd that PfHAD1 dephosphorylates a variety
of sugar phosphates, including glycolytic intermediates. Loss of PfHAD1 is required for
fosmidomycin resistance. Parasites lacking PfHAD1 have increased MEP pathway meta-
bolites, particularly the DXR substrate, deoxyxylulose 5-phosphate. PfHAD1 therefore
controls substrate availability to the MEP pathway. Because PfHAD1 has homologues in plants
and bacteria, other HAD proteins may be MEP pathway regulators.
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I
soprenoids are the largest and most diverse class of
biomolecules1. Isoprenoids perform essential cellular
functions such as respiration (ubiquinone) and membrane
localization of proteins (prenylation). There is considerable
commercial interest in the production of isoprenoid-derived
secondary metabolites as pharmaceuticals (for example,
artemisinin and taxol) and biofuels. Isoprenoids are synthesized
from two ﬁve-carbon precursor molecules, isopentenyl pyro-
phosphate and its isomer, dimethylallyl pyrophosphate. Two
metabolically and enzymatically distinct pathways exist for the
synthesis of isopentenyl pyrophosphate and dimethylallyl pyro-
phosphate. Archaea, fungi and animals utilize a mevalonate-
dependent pathway. In contrast, plastid-containing eukaryotes
and most bacteria use an alternate route that proceeds
through the key metabolite methylerythritol phosphate (MEP)
(Fig. 1) (ref. 2).
In the MEP pathway, two glycolytic intermediates (glyceralde-
hyde 3-phosphate (gly3P) and pyruvate) are combined to
generate deoxyxylulose 5-phosphate (DOXP) by DOXP synthase
(DXS; E.C. 2.2.1.7). DOXP is subsequently reduced and
isomerized to MEP in the ﬁrst dedicated step of the MEP
pathway, catalysed by deoxyxylulose phosphate reductoisomerase
(DXR; E.C. 1.1.1.267). These ﬁrst two steps of the MEP pathway
are rate limiting in MEP-dependent isoprenoid biosynthesis3–5.
Organisms may increase ﬂux through the MEP pathway by
increasing DXS and DXR production, or by increasing substrate
availability for these enzymes6.
The phosphonic acid antibiotic, fosmidomycin (FSM), compe-
titively inhibits DXR in vitro7. Metabolic proﬁling of FSM-treated
cells conﬁrms that FSM inhibits MEP pathway metabolism within
cells8. The growth effects of FSM are rescued by supplementation
with downstream isoprenoids, conﬁrming that the biological
effects of FSM are mediated through isoprenoid biosynthesis
inhibition8–10. These studies validate the use of FSM as a speciﬁc
tool to probe the MEP pathway. Because chlorophyll biosynthesis
requires MEP pathway-derived isoprenoids, FSM is a herbicide11.
FSM resistance in the model plant, Arabidopsis thaliana,
has been used to gain insight into MEP pathway regulation,
and these studies have revealed post-transcriptional control of
MEP pathway enzymes through an RNA metabolism protein
(Rif10) (ref. 12).
In contrast, there is little understanding of the MEP pathway
regulation in non-model organisms. The malaria parasite,
Plasmodium falciparum, depends on de novo isoprenoid bio-
synthesis through the MEP pathway9,13. Since drug resistance is
one of the greatest challenges in malaria eradication, the
MEP pathway is an attractive parasite-speciﬁc target for
antimalarial drug development. As in plants, the MEP pathway
in apicomplexan parasites is localized to a plastid-like organelle.
The parasite organelle is called the apicoplast14, and isoprenoid
synthesis may be the only required function of the apicoplast
during blood-stage development9,10. Though not photosynthetic,
the apicoplast shares a similar endosymbiotic origin with the
plant chloroplast15. This uniquely positions P. falciparum in
studies of MEP pathway biology as a plastid-containing eukaryote
that is also a globally important pathogen.
Here, to gain insight into how malaria parasites regulate
isoprenoid precursor synthesis, we screen for P. falciparum
strains able to survive MEP pathway inhibition by FSM. We
uncover the ﬁrst regulator of MEP pathway metabolism in
malaria parasites, PF3D7_1467300 (PfHAD1), a member of the
haloacid dehalogenase (HAD) superfamily. Using detailed
structural and biochemical studies, we show that FSM resistance
is correlated with changes in PfHAD1 that ablate function.
Further, we ﬁnd that PfHAD1 is a cytosolic sugar phosphatase
that dephosphorylates the intermediates of glycolysis. Loss of
PfHAD1 function increases substrate availability to the MEP
pathway and increases levels of isoprenoid precursors, thus
conferring FSM resistance. Since close homologues of PfHAD1
are present in other MEP pathway-containing organisms, sugar
phosphatases may represent a common strategy to regulate MEP
pathway ﬂux.
Results
Selection of FSM-resistant (FSMR) P. falciparum. The
MEP pathway is essential for the synthesis of isoprenoids in
P. falciparum8,9,13. The phosphonic acid antibiotic FSM
speciﬁcally inhibits this pathway, primarily via competitive
inhibition of PfDXR7 (Fig. 1). A FSM-sensitive 3D7 parental
strain was subjected to FSM treatment at Btwo to fourfold the
wild-type half maximal inhibitory concentration (IC50; Fig. 2a,
Supplementary Table 1). This selection generated 19 independent
FSMR strains of P. falciparum with increased IC50s for FSM
ranging from 1.5–8.1 mM (Fig. 2b, Supplementary Table 1). FSMR
strains are also resistant to the related antibiotic, FR-900098 (ref.
16) (Supplementary Fig. 1).
FSM resistance has been associated with copy number
variations in the FSM target, PfDXR (PF3D7_1467300) (ref.
17). However, copy number changes that result in drug resistance
often revert when selection is relieved18. To discourage PfDXR
copy number variants, FSMR strains were cycled on and off drug
treatment. All strains maintain their resistance phenotype after
prolonged growth without FSM, and no changes in PfDXR
transcript levels are observed in FSMR strains (Supplementary
Fig. 2).
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Figure 1 | The MEP pathway for isoprenoid biosynthesis. The MEP pathway for the synthesis of isoprenoids is speciﬁcally inhibited by FSM. FSM
competitively inhibits PfDXR and indirectly inhibits PfIspD8. CDP-ME, 4-diphosphocytidyl-2-C-methylerythritol; CDP-MEP, 4-diphosphocytidyl-2-C-
methyl-D-erythritol 2-phosphate; DMAPP, dimethylallyl pyrophosphate; DXR, DOXP reductase; IPP, isopentenyl pyrophosphate; IspD, CDP-ME synthase;
IspE, CDP-ME kinase; IspF, MEcPP synthase.
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To control for genetic changes arising from prolonged culture
or culture stresses, we performed control selections in which the
parental 3D7 strain was cultured continuously for 43 months
and, in some cases, was subjected to culture stresses such as
depleted or incomplete media and aged (490 days) erythrocytes.
These strains retain their FSM sensitivity as measured by IC50
(mean IC50 1.8±0.4 mM).
FSMR strains are enriched for genetic changes in PfHAD1. To
uncover genetic changes correlated with FSM resistance, we
genotyped the parent strain, six FSMR strains, and two control
strains by whole genome sequencing with at least 15 genome
coverage. Sanger sequencing was used to verify single-nucleotide
polymorphisms (SNPs) and insertion–deletions (indels) and to
genotype loci of interest in strains whose genomes were not
sequenced. We prioritized genetic changes found in coding
regions and did not evaluate changes in highly variable loci (such
as var and riﬁn genes)19,20. A list of SNPs uniquely identiﬁed in
the FSMR strains is found in Supplementary Data 1. The resulting
data reveal a signiﬁcant enrichment for nonsynonymous changes
in PF3D7_1033400 in FSMR strains compared with control
strains (Fig. 3a). We hereafter refer to PF3D7_1033400 as
PfHAD1. Fourteen of the 19 FSMR strains have a nonsynonymous
change in PfHAD1, while seven control laboratory strains do not
have any sequence changes in PfHAD1 (P¼ 0.0012, Fisher’s Exact
Test).
Eleven alleles were represented in the 14 strains with PfHAD1
changes. Of these alleles, four indels and two nonsynonymous
substitutions result in a truncated amino acid sequence
(Supplementary Table 1). The remaining ﬁve alleles are
nonsynonymous substitutions that result in single amino acid
changes. Four of these alleles are predicted to have deleterious
effects on protein function by Polyphen-2, an algorithm for
predicting the probability of functional effects of missense
mutations (Polyphen-2 score 40.9)21 (Supplementary Table 1).
Overall, FSMR strains are signiﬁcantly enriched for likely
deleterious changes in PfHAD1, a previously uncharacterized
gene, compared with FSM-sensitive control strains.
In addition to the 3D7 PfHAD1 allele that we designate as wild-
type, a nonsynonymous N70S variant has also been reported in
sequenced clinical and laboratory isolates of P. falciparum22,23.
This allele is not predicted to be deleterious (Polyphen-2
score¼ 0.007). Two strains that possess the N70S allele, HB3
and Dd2, are not resistant to FSM (FSM IC50s of 1.3±0.2 mM and
0.6±0.09 mM, respectively). Five additional strains whose
sequence data are available on public databases (7G8, D10,
GHANA1, K1 and V1_S, plasmodb.org, accessed 4 November
2013) also possess the N70S allele. The minimal sequence
variation in this gene in natural populations suggests that
PfHAD1 has an important cellular function in P. falciparum.
PfHAD1 is a Cof-like hydrolase member of the HAD super-
family. Sequence homology places PfHAD1 in the HAD super-
family (Pfam PF08282) (ref. 24). Members of this large
superfamily are found in all three kingdoms of life and catalyse
carbon- or phosphoryl-transfer reactions25. The promiscuous
substrate proﬁles and low levels of sequence similarity between
HADs have made determining the in vivo function of many
superfamily members difﬁcult26.
Within the HAD superfamily, PfHAD1 has the greatest
sequence similarity to the Cof-like hydrolase subfamily (Interpro
IPR000150) (ref. 27). This family is named for an Escherichia coli
enzyme involved in thiamin biosynthesis26,28. Most members of
the Cof subfamily are bacterial and most remain uncharacterized.
Biochemical characterization suggests that members of this family
utilize phosphorylated sugar substrates26,29.
Sequence changes map to core and active site of PfHAD1.
PfHAD1 changes found in FSMR strains map along the
entire gene body (Fig. 3a). To deﬁne the structural basis for
the role of these point mutations in PfHAD1 function, we solved
the crystal structure of PfHAD1 to 2.05Å (Fig. 3b, Table 1). Clear
electron density was not observed for the 6xHis tag in either
chain, or the amino-terminal (N-terminal) region in chain B
(residues 1–19), and were therefore not modelled. Like other
members of the HAD superfamily, PfHAD1 consists of two
distinct domains: a catalytic core domain (residues 1–106
and 212–288) and a cap domain (residues 107–211). The cap
domain is inserted into the linker immediately following the third
beta-strand.
The four sequence motifs required for the catalysis25 of HAD
superfamily members are structurally conserved in PfHAD1:
motif I—DXD sequence at the end of strand I; motif II—a
conserved threonine/serine at the end of strand II; motif III—a
conserved lysine at the N terminus of the helix before strand IV;
motif IV—a DD, GDxxxD or GDxxxxD on strand IV (Fig. 3c)25.
The sequence 27-DLD-29 in PfHAD1 corresponds to motif I,
Thr-61 corresponds to motif II, Lys-215 corresponds to motif III
and the sequence 237-GDGEND-242 corresponds to the
GDxxxD signature of motif IV. These structural motifs make
up the substrate-binding site, located on the interface between the
core and cap domains. These motifs are conserved among
PfHAD1 homologues found in MEP pathway-containing
organisms, including E. coli, Mycobacterium tuberculosis, the
alga Chlamydomonas reinhardtii and Arabidopsis thaliana
(Fig. 3c).
Catalysis by PfHAD1 is metal–ion dependent, and the side
chains of Asp-27 and Asp-238, and the backbone carbonyl
oxygen of Asp-29, coordinate a magnesium ion in the structure
(Fig. 3c). On the basis of homology to other HAD family
































Figure 2 | Generation of FSM-resistant (FSMR) P. falciparum. (a) Schematic of selection of FSMR strains. (b) FSMR strains exhibit a range of resistance
phenotypes. FSMR strains have an average FSM IC50 of 4.8±0.4mM compared with the wild-type IC50 of 1.1±0.2 mM. A complete list of strains
and their IC50 values are found in Supplementary Table 1.
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phosphate compounds binds by coordinating the magnesium ion
and the side chains of Thr-61, Lys-215 and Asp-29. Asp-27 is
predicted to perform nucleophilic attack of the phosphate group.
As PfHAD1 was crystallized in the absence of a sugar phosphate
substrate, a chloride ion occupies the likely phosphate-binding
site based on structural similarity to other HAD sugar
phosphatases.
The point mutations identiﬁed in FSMR strains (T26R, G30E,
A60E, W130R and Y148C) were mapped onto the PfHAD1
crystal structure (Fig. 3b). Trp-130 and Tyr-148 are located in a
tightly packed hydrophobic inner region of the cap domain.
Mutations of these aromatic residues to a charged arginine and a
small polar cysteine residue, respectively, likely result in the
misfolding of the cap domain. Similarly, Thr-26 and Ala-60 are
located in the hydrophobic inner region of the core domain, and
mutation of these residues to a charged glutamate and arginine,
respectively, are predicted to result in the misfolding of the core
domain. Finally, Gly-30 is located in the active site of PfHAD1,
and a mutation to a glutamate with a much larger side chain is
predicted to interfere with substrate binding. Together, the
structural mapping of FSMR PfHAD1 mutations suggests that,
similar to nonsense mutations, the FSMR nonsynonymous
mutations result in the loss of function of PfHAD1 activity
through drastic changes in the core or catalytic regions of
PfHAD1. The N70S variant is not suspected to have changes in
activity, as Asn-70 is located on the surface of PfHAD1 and away
from the substrate-binding site.
FSMR PfHAD1 alleles result in loss of phosphatase activity. We
next investigated the enzymatic activity of PfHAD1. Because
PfHAD1 has sequence homology to known phosphatases26
(Fig. 3c), we predicted that PfHAD1 is also a phosphatase. We
expressed and puriﬁed recombinant wild-type PfHAD1, the N70S
variant and three full-length variants (G30E, A60E and Y148C)
found in FSMR strains. Recombinant PfHAD1 is active against a
non-speciﬁc phosphatase substrate, para-nitrophenyl phosphate
(pNPP) (Fig. 4). This compound has been used in phosphatase
screens as an effective indicator of phosphatase activity26,30.
Activity against pNPP is signiﬁcantly reduced in each of the
FSMR PfHAD1 variants (Fig. 4). The N70S variant found in
sequenced isolates has activity similar to the wild-type enzyme
(P¼ 0.59, unpaired Student’s t-test).
PfHAD1 complementation restores FSM sensitivity. Because
our FSMR strains are enriched for changes that result in loss of
PfHAD1 function, we conﬁrmed that restoring PfHAD1 expres-
sion would restore sensitivity to FSM. Using a piggyBac trans-
poson system31, functional PfHAD1 was expressed in FSMR
strain AM1, which possesses a premature truncation at amino
acid 208 of the PfHAD1 locus and lacks detectable PfHAD1
(Fig. 5a). The expression construct produces green ﬂuorescent
protein (GFP)-tagged PfHAD1. The rescued strain, AM1
Hsp110:PfHAD1-GFP, retains its original mutation at the
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Figure 3 | FSMR variants map to the core and active site regions of PfHAD1. (a) Schematic of PfHAD1 variants found in FSMR strains. Six of the
alleles result in premature stop codons. Five alleles produce full-length protein. N70S is a nondeleterious allele reported from sequenced clinical and
laboratory isolates. Conserved active site motifs are shown as black boxes25. (b) Overall structure of PfHAD1 with the core domain in blue, cap domain in
green and polymorphic residues mapped in yellow. Residues W130 and Y148 are located in the hydrophobic inner region of the cap domain. Residues
T26 and A60 are located in the hydrophobic inner region of the core domain. Residue G30 is located in the substrate-binding site. (c) The backbone
carbonyl oxygen of Asp-29 and the side chains of Asp-27 and Asp-238 coordinate a magnesium ion to form the active site. The side chains of Asp-29,
Thr-61, and Lys-215 coordinate a chloride ion, and are correctly positioned to coordinate a phosphate group on substrate binding. These active-site residues
are conserved in PfHAD1 homologues from organisms possessing the MEP pathway. Alignment was produced in T-Coffee55 using default parameters.
Accession codes for NCBI protein sequences: E. coli YidA, EOU46719;M. tuberculosis Rv3813c, NP_218330; C. reinhardtii FER_156463, ADF43173; A. thaliana
At2g25870, ABO38782.
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The expression pattern of Hsp110 is similar to that of PfHAD1
(ref. 32). The expression of functional PfHAD1 restores FSM
sensitivity in AM1. While the FSM IC50 of AM1 is 5.5±1.5 mM,
AM1 Hsp110:PfHAD1-GFP has an IC50 of 1.4±0.2 mM, similar
to the parental IC50 of 1.1±0.2 mM, indicating that loss of
PfHAD1 function leads to FSM resistance in our strains (Fig. 5b).
PfHAD1 is a sugar phosphatase. Within the HAD superfamily,
PfHAD1 has the greatest sequence similarity to the Cof-like
hydrolase subfamily of sugar phosphatases. We assayed recom-
binant wild-type PfHAD1 with a number of phosphorylated
sugar substrates (Fig. 6). PfHAD1 has a wide substrate utilization
proﬁle and low substrate speciﬁcity, consistent with other mem-
bers of this enzyme family26,33,34. PfHAD1 does not directly
utilize FSM as a substrate.
In vitro, PfHAD1 is most active against monophosphorylated
three to six-carbon monosaccharides, including intermediates of
glycolysis, the pentose phosphate pathway and the MEP pathway
(Fig. 6). Kinetic parameters for the top three substrates as well as
gly3P, a MEP pathway precursor, can be found in Supplementary
Table 2. The substrate proﬁle of PfHAD1 is similar to that of
related HADs in E. coli and A. thaliana26,33. Like other HADs,
PfHAD1 dephosphorylates a variety of substrates in vitro.
Catalytic efﬁciencies (kcat/Km) for the four measured substrates
were within an order of magnitude and do not clearly indicate a
preferred in vivo substrate, which is typical of this enzyme class.
None of the puriﬁed recombinant FSMR PfHAD1 variants have
signiﬁcant activity against sugar phosphate substrates (maximum
mean activity o0.9 mmolmin 1mg 1 for all variants against
man6P, G6P, F6P, rib5P, gly3P and DHAP).
PfHAD1 is localized to the cytoplasm. MEP pathway enzymes
are localized to the apicoplast in P. falciparum14,35. To help
elucidate the mechanism by which PfHAD1 affects MEP pathway
function, we examined the subcellular localization of PfHAD1.
We raised speciﬁc polyclonal rabbit antisera against recombinant
PfHAD1 and performed confocal immunoﬂuorescence to
localize PfHAD1. PfHAD1 is highly expressed in blood-stage
parasites36. PfHAD1 appears to be cytoplasmic and has minimal
overlap with the apicoplast marker ACPL-GFP (described by
Waller, et al.37; Fig. 7). Live ﬂuorescent localization of PfHAD1-
GFP (in strain AM1 Hsp110:PfHAD1-GFP) was similar to that
of PfHAD1 immunolocalization in the ﬁxed parental strain
(Supplementary Fig. 4). In addition, PfHAD1 lacks an apicoplast
localization signal as predicted by the PlasmoAP and PATS
algorithms38,39. Given the localization of PfHAD1, the enzyme
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Figure 4 | PfHAD1 FSM-resistance alleles result in loss of phosphatase
activity. Displayed are the means±s.e.m. of enzyme activity from at least
three independent experiments. P-values were determined using a one-way
analysis of variance (Tukey’s post test, a¼0.05) in GraphPad Prism
software. ‘NS’¼ not signiﬁcant (P40.05). ‘No enz.’¼ no enzyme. We were
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Figure 5 | Loss of PfHAD1 is required for FSM resistance. Data shown are
representative of at least three independent experiments. (a) Immunoblot
of the parent strain, FSMR strain AM1 and AM1 Hsp110:PfHAD1-GFP. Full
blots are shown in Supplementary Fig. 3. Marker units are kilodaltons (kDa).
Top panel was probed with anti-PfHAD1 antisera, and the bottom panel was
probed with anti-heat shock protein 70 (hsp70) antisera as a loading
control. Expected approximate protein masses: native PfHAD1, 33 kDa;
PfHAD1-GFP, 60 kDa; hsp70, 74 kDa. (b) FSM IC50s of the parent strain,
FSMR strain AM1, and AM1 Hsp110:PfHAD1-GFP. Displayed are the
means±s.e.m. The parent strain has a FSM IC50 of 1.1±0.2mM, while AM1
has an IC50 of 5.5±1.5mM. Expression of PfHAD1-GFP in AM1 results in an
IC50 of 1.4±0.2 mM. Data shown are mean and are normalized such that
100% growth is deﬁned by that of untreated cells and 0% growth is deﬁned
as the smallest value in each data set.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5467 ARTICLE
NATURE COMMUNICATIONS | 5:4467 |DOI: 10.1038/ncomms5467 | www.nature.com/naturecommunications 5
& 2014 Macmillan Publishers Limited. All rights reserved.
likely utilizes phosphorylated sugars available in the cytoplasm,
such as glycolytic intermediates.
FSMR strains increase levels of MEP pathway intermediates.
Since PfHAD1 dephosphorylates glycolytic intermediates,
we predicted that the loss of PfHAD1 function would
increase substrate availability to the MEP pathway, which
requires gly3P and pyruvate. We evaluated the levels of MEP
pathway intermediates in eight FSMR P. falciparum strains
with PfHAD1 changes, using our previously described
quantitative liquid chromatography-mass spectrometry method8
(Fig. 8, Supplementary Table 3). Parental 3D7 and eight FSMR
strains were treated þ / FSM for 10 h and the levels of
MEP intermediates were quantiﬁed in each strain. Our
method quantiﬁes cellular levels of 1-deoxy-D-xylulose 5-
phosphate (DOXP), 2-C-methylerythritol 4-phosphate (MEP),
4-diphosphocytidyl-2-C-methylerythritol and 2-C-methyl-D-
erythritol 2,4-cyclopyrophosphate (MEcPP).
FSMR strains with PfHAD1 mutations show an overall increase

















































































Figure 6 | PfHAD1 dephosphorylates sugar phosphates, including MEP pathway intermediates. Displayed are the means±s.e.m. of the enzyme activity
from at least three independent experiments. DHAP, dihydroxyacetone phosphate; Ery4P, erythrose 4-phosphate; Fru1P, fructose 1-phosphate; Fru6P,
fructose 6-phosphate; Fru1,6bisP, fructose 1,6-bisphosphate; Gal1P, galactose 1-phosphate; Glc2P, glycerol 2-phosphate; Gln1P, glucosamine 1-phosphate;
Glu1P, glucose 1-phosphate; Glu6P, glucose 6-phosphate; Man1P, mannose 1-phosphate; Man6P, mannose 6-phosphate; PEP, phosphoenolpyruvate; Rib5P,
ribose 5-phosphate; Ribu5P, ribulose 5-phosphate; Sedo7P, sedoheptulose 7-phosphate; Sorb6P, sorbitol 6-phosphate; Tre6P, trehalose 6-phosphate;











Hoechst αGFP αPfHAD1 Merge
Figure 7 | PfHAD1 is expressed in blood-stage parasites and is localized to the parasite cytoplasm. Immunoﬂuorescence confocal microscopy of ACPL-
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MEP CDP-ME MEcPP
Figure 8 | Increased levels of MEP pathway intermediates in FSMR strains with the loss of PfHAD1 function. Ring-stage parental and FSMR
P. falciparum parasites were treated þ / 5mM FSM for 10 h. Displayed are the means±s.e.m. of the metabolite levels from at least three independent
experiments. Representative FSMR strain E1 is shown, which possesses the K10X PfHAD1 allele. The complete dataset is found in Supplementary
Table 3. CDP-ME, 4-diphosphocytidyl-2-C-methylerythritol.
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parental strain, FSMR strains have a 55.2±5.9-fold increase in the
levels of DOXP, the substrate for PfDXR (median Po0.01,
unpaired Student’s t-test). This increase is maintained during
treatment with FSM (78.7±10.1-fold increase, median Po0.01;
Fig. 8, Supplementary Table 3) and would allow for DOXP to
compete with FSM binding to PfDXR. Increased DOXP levels are
not due to the increased transcript levels of PfDXS, the enzyme
that produces DOXP (Supplementary Fig. 2). FSM-treated FSMR
strains also have an increase in MEcPP levels compared with the
parental strain (2.7±0.43-fold, median Po0.01).
In other systems, FSM resistance is due to the lack of FSM
uptake or FSM efﬂux40–42. Metabolic proﬁling of FSMR parasites
suggests that is not the mechanism of resistance in our strains.
FSM treatment of FSMR strains results in metabolic changes that
are still consistent with inhibition of PfDXR, the target of FSM.
Speciﬁcally, the levels of the upstream metabolite DOXP increase,
and levels of distal metabolites, such as MEcPP, decrease (Fig. 8,
Supplementary Table 3)8. Our data are most consistent with a
change in a metabolic regulator outside the MEP pathway that
inﬂuences production of pathway intermediates, namely DOXP.
Discussion
In this study, we describe the genetic, biochemical, structural and
metabolic basis for the resistance to the MEP pathway inhibitor
FSM in the malaria parasite, Plasmodium falciparum. Our study
represents a powerful use of next-generation sequencing to
facilitate a forward genetics approach in a non-model organism to
identify a new regulator of an essential biochemical pathway, the
MEP pathway of isoprenoid biosynthesis.
We identify a member of the HAD superfamily, PfHAD1,
whose loss-of-function confers FSM resistance in P. falciparum.
To our knowledge, PfHAD1 is the ﬁrst cellular factor that
regulates the MEP pathway in P. falciparum. PfHAD1 has
structural similarity to other members of the HAD superfamily,
retains the motifs necessary for catalysis, and is active against
sugar phosphates. Loss of PfHAD1 function causes dramatically
increased levels of MEP pathway metabolites, particularly DOXP,
the substrate of DXR. Our work suggests a model of PfHAD1
function, shown in Fig. 9. We propose that PfHAD1 is a negative
regulator of the MEP pathway. It typically catalyses the depho-
sphorylation of cytosolic phosphometabolites, such as glycolytic
intermediates, to decrease the availability of substrates to the
MEP pathway. Loss of sugar phosphatase activity in FSMR
malaria parasites results in increased pools of DOXP, which
overcomes competitive inhibition of PfDXR by FSM.
FSMR malaria strains are highly enriched for genetic changes in
the PfHAD1 locus. In our study, we identiﬁed 11 separate
deleterious genotypic changes in PfHAD1. If FSM is approved for
clinical use, these changes may represent the genetic biomarkers
of FSM resistance. While other genetic changes are also present in
the FSMR strains (Supplementary Data 1), our data indicate that
the loss of PfHAD1 is the primary driver of resistance. In
addition, changes in PfHAD1 genotype correlate not only with
FSM resistance, but also with increased cellular levels of
isoprenoid precursor metabolites. Complementation of a deleter-
ious PfHAD1 allele restores FSM sensitivity. These ﬁndings
strongly support that the primary biochemical change responsible
for these phenotypes is the loss of PfHAD1 function.
PfHAD1 is a member of the large, diverse HAD superfamily of
aspartate nucleophile hydrolases, and belongs to the subfamily of
Cof-like hydrolases (Interpro IPR00150). Many HAD family
members have been structurally and enzymatically character-
ized26,29,33,34. However, the cellular functions of this group of
enzymes are largely unknown. The Cof-like hydrolases are absent
from animal and fungal genomes, but are highly expanded in
bacteria. In addition, Cof-like hydrolases are uniformly present in
eukaryotes that possess a plastid-like organelle, such as
chloroplast-containing plants, and the apicomplexan parasites,
such as P. falciparum. This phylogeny parallels that of the MEP
pathway, which is also exclusive to many bacteria and plastid-
containing eukaryotes, and absent in animals or fungi. Since few
studies have addressed the potential biological function of these
enzymes, additional work is required to determine whether
PfHAD1 homologues represent regulators of isoprenoid
biosynthesis in other MEP pathway-containing organisms.
Evidence suggests that this may be the case in bacteria, since
the E. coli PfHAD1 ortholog YidA was identiﬁed in a colorimetric
screen of E. coli for increased lycopene production43.
During its intraerythrocytic development cycle, glycolysis is the
primary source for ATP generation in P. falciparum44. As a result,
the malaria parasite has great capacity for glucose uptake and
carbon ﬂux through glycolysis. PfHAD1 has a broad substrate
proﬁle, and readily dephosphorylates a range of three to six-
carbon monophosphorylated substrates, including glycolytic and
pentose phosphate intermediates, as well as MEP pathway
metabolites. Given this promiscuity, it is unclear which
metabolite/s represent the natural in vivo substrate/s for
PfHAD1 and other Cof-like subfamily members. Thus, our
studies do not distinguish which upstream metabolic step is
regulated by PfHAD1. In addition, it is unclear why malaria
parasites produce an enzyme whose activity would decrease
glycolysis and ATP production. Genetic conservation of PfHAD1
in clinical and laboratory isolates of P. falciparum, as well as
among PfHAD1 homologues in divergent organisms, suggests
that these proteins have important cellular functions under
typical growth conditions.
The MEP pathway is an important target for the development
of small-molecule inhibitors, since this pathway is absent in
animals but essential in plants and key human pathogens,
including malaria parasites and M. tuberculosis. Our studies
highlight what may be a particular challenge in developing novel





















Figure 9 | Model of PfHAD1 function. PfHAD1 (blue arrows) may
dephosphorylate the intermediates of glycolysis. Loss of PfHAD1 may
increase local levels of sugar phosphates and increase the substrate
availability to the apicoplast MEP pathway (green). The use of PEP as a
substrate is unlikely, given the poor PfHAD1 activity against this substrate
in vitro (Fig. 6). Green reactions and substrates are part of the MEP
pathway. PﬁTPT and PfoTPT are transporters responsible for the import of
PEP and DHAP into the apicoplast56,57. The conversion of PEP and DHAP
into pyruvate and gly3P, respectively, are catalysed by apicoplast-localized
pyruvate kinase (PK)58 and triosephosphate isomerase (TPI)59. DHAP,
dihydroxyacetone phosphate; DMAPP, dimethylallyl pyrophosphate; IPP,
isopentenyl pyrophosphate; PEP, phosphoenolpyruvate.
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of growth in the presence of FSM, drug treatment still
substantially reduces levels of the distal MEP pathway metabolite,
MEcPP. Following FSM treatment, MEcPP levels in FSMR strains
are reduced toB20% of the concentrations present in untreated,
wild-type parasites. This suggests that, at least in malaria
parasites, cells direct more ﬂux through the MEP pathway than
is absolutely required for development, and therefore, they are
capable of growth even when MEP pathway metabolism is
substantially reduced. As novel MEP pathway inhibitors are
developed, it appears that these compounds must achieve a
sobering near-complete inhibition of the cellular MEP pathway in
order to inhibit malaria parasite growth.
Methods
Reagents. Reagents were purchased from Sigma-Aldrich unless otherwise
indicated.
Maintenance of P. falciparum cultures. The P. falciparum strain used for FSM
selection is derived from genome reference strain 3D7 (ref. 45). The ACPL-GFP
(expresses apicoplast-targeted GFP) strain used for immunoﬂuorescence
microscopy is described in Waller, et al.37. 3D7 and ACPL-GFP were obtained from
the Malaria Research and Reference Reagent Resource Center (strains MRA-102
and MRA-568, respectively, MR4, ATCC, Manassas, Virginia). Unless otherwise
stated, P. falciparum strains were cultured at 37 C in a 2% suspension of human
erythrocytes in RPMI-1640 medium (Sigma-Aldrich, SKU R4130) supplemented
with 27mM sodium bicarbonate, 11mM glucose, 5mM HEPES, 1mM sodium
pyruvate, 0.37mM hypoxanthine, 0.01mM thymidine, 10 mgml 1 gentamycin
and 0.5% albumax (Life Technologies) in a 5% O2/5% CO2/90% N2 atmosphere, as
previously described8,46. Culture growth was monitored by microscopic analysis of
Giemsa-stained blood smears.
Generation of FSMR P. falciparum. A 3D7 parental strain was cloned by limiting
dilution and used as the parental strain for all selections. Independent selections are
deﬁned as those cultures that were cultured in separate wells before and during
selection. The parental strain was at 4% parasitemia in 4-ml cultures at the
initiation of FSM selection. Parasites were initially cultured in media containing
0.5–1 mM FSM and gradually scaled to ﬁnal concentrations of 2–4 mM FSM. The
following FSMR strains were cloned by limiting dilution: E1, D6, MK1, D3, AM1
and AM2.
Quantiﬁcation of FSM resistance. Asynchronous P. falciparum cultures were
diluted to 1% parasitemia and were treated with FSM (Life Technologies) at
concentrations ranging from 0.025–500 mM. Growth inhibition assays were per-
formed in opaque 96-well plates at 100 ml culture volume. After 3 days, parasite
growth was quantiﬁed by measuring DNA content using Picogreen (Life Tech-
nologies), as previously described47. Picogreen ﬂuorescence was measured on a
FLUOstar Omega microplate reader (BMG Labtech) at 485 nm excitation and
528 nm emission. IC50 values were calculated by nonlinear regression analysis using
GraphPad Prism software.
Whole genome sequencing and variant discovery. Genomic DNA was isolated
from P. falciparum cells by a standard phenol-chloroform extraction and
ethanol precipitation protocol48. Sequencing libraries were prepared and sequenced
by the Washington University Genome Technology Access Center (GTAC).
Brieﬂy, 5 mg of genomic DNA was sheared to an average size of 175 bp. Fragments
were end repaired and an ‘A’ base was added to the 30 end. Adapters containing
index sequences were ligated to the fragments. Resulting libraries were sequenced
on an Illumina HiSeq 2000 to obtain 101 bp paired end reads. Bioinformatic
analyses were performed by GTAC. Reads were not merged, but were aligned to the
P. falciparum reference genome using Novoalign (Novocraft Technologies).
PCR duplicates were removed using Picard and variants were analysed using
SAMtools. SNPs were called if present in 450% of the reads. For all samples, at
least 75% of coding regions were sequenced at Z5 coverage. All whole
genome sequencing data is available in the NCBI BioProject database and Sequence
Read Archive.
Sanger sequencing of PfHAD1. The region of interest was ampliﬁed from
P. falciparum genomic DNA using the following gene-speciﬁc primers: 50-GGTT
CAAGGGTGATAGATAGGA-30, 50-CGAAGGTCCAACATAAGCAG-30 , 50-ATG
CACGAAATTGTAGATAAGAATG-30, 50-AATTCATGTATCTCCATTTTCA
AGTC-30 and 50-GATCACTACATTTTGGACGTACAC-30. Puriﬁed PCR pro-
ducts were sequenced by the Washington University Protein and Nucleic Acid
Laboratory using BigDye Terminator v3.1 Cycle Sequencing reagents (Life Tech-
nologies). Chromatogram ﬁles were analysed using DNAStar SeqMan software.
Representative traces for all strains are available through the NCBI Trace Archive.
Recombinant expression and puriﬁcation of PfHAD1 variants. All PfHAD1
(PlasmoDB ID PF3D7_1033400) alleles were ampliﬁed from P. falciparum geno-
mic DNA using the following primers: 50–CTCACCACCACCACCACCATATG
CACGAAATTGTAGATAAGAA-30 and 50- ATCCTATCTTACTCACTTATA
TGTCACAGAATGTCTTCA-30 . The PCR product was cloned by ligation-inde-
pendent cloning into vector BG1861 (ref. 49), which introduces an N-terminal
6xHis tag and the construct was veriﬁed by Sanger sequencing. BG1861:6xHis-
PfHAD1 was transformed into BL21(DE3)pLysS Escherichia coli cells (Life
Technologies). Following induction with isopropyl-b-D-thiogalactoside, cells were
collected by centrifugation and stored at  20 C. Pellets were resuspended in lysis
buffer containing 10mM Tris HCl (pH 7.5), 20mM imidazole, 01mM MgCl2,
01mM dithiothreitol, 1mgml 1 lysozyme, 100U benzonase and Complete Mini
EDTA-free protease inhibitor tablets (Roche Applied Science). 6xHis-PfHAD1 was
bound to nickel agarose beads (Gold Biotechnology), eluted in 300mM imidazole,
20mM Tris HCl (pH 7.5) and 150mM NaCl, and dialyzed in buffer lacking
imidazole before analysis. Protein was ﬂash frozen and stored at  80 C.
Crystallization and structure determination. PfHAD1 was further puriﬁed by
gel chromatography using a HiLoad 16/600 Superdex 200 pg column (GE
Healthcare) equilibrated with 10mM Tris (pH 8.0), 150mM NaCl and 5mM
dithiothreitol. The fractions containing PfHAD1 were pooled and concentrated to
20mgml 1 using a centrifugal ﬁlter.
Crystals of PfHAD1 were obtained by vapour diffusion using hanging drops
equilibrated at 18 C against 500 ml of a reservoir containing 0.1M HEPES (pH 7.5)
and 20–25% PEG 8000. Crystals were cryo-protected with 0.1M HEPES (pH 7.5)
and 30% PEG 8000 before ﬂash-freezing under liquid nitrogen for data collection.
X-ray data were collected from a single crystal using a wavelength of 1Å at
synchrotron beamline 4.2.2 of the Advanced Light Source in Berkeley, CA. Data
were processed with XDS50 and the coordinates from PDB 2B30 were used as a
search model for phase determination by molecular replacement using PHENIX51.
Rigid-body reﬁnement followed by automatic model rebuilding were performed in
PHENIX51. Subsequent iterated manual building/rebuilding and reﬁnement of
models were performed using Coot52 and PHENIX51, respectively. The structure
validation server MolProbity53 was used to monitor reﬁnement. The ﬁnal reﬁned
model results in a Ramachandran plot with 96.75% of residues in the favored
region and 3.25% in the allowed region. A complete summary of the ﬁnal
crystallographic reﬁnement statistics are given in Table 1 and a stereo image of a
representative region of the electron density map is shown in Supplementary Fig. 5.
Figures were prepared using PyMOL Molecular Graphics System, Version 0.99rc6,
Schro¨dinger, LLC. Structure data is deposited in the RSCB Protein Structure
Database.
pTEOE110:PfHAD1-GFP plasmid construction. The construct used to express
PfHAD1 in FSMR strains, pTEOE110, was a gift from Daniel Goldberg
(Washington University, St. Louis). The construct contains the heat shock protein
110 (PF3D7_0708800) 50 UTR54 and a carboxyl-terminal GFP tag. The human
dihydrofolate reductase selectable marker confers resistance to WR92210. These
sites are ﬂanked by inverted terminal repeats31 that allow for integration of the
segment containing the Hsp110 50 UTR, the gene of interest, GFP and human
dihydrofolate reductase into the genome, facilitated by a co-expression from a
plasmid encoding the piggyBac transposase (pHTH, MRA912, MR4, ATCC,
Manassas, Virginia).
PfHAD1 was ampliﬁed using the following primers: 50-CATGCTCGAGATGC
ACGAAATTGTAGATAAGAA-30 and 50-CATGCCTAGGTATGTCACAGAA
TGTCTTCAAG-30 . The resulting PCR product was cloned into the XhoI and AvrII
sites in pTEOE110 to generate pTEOE:PfHAD1. Successful insertion was
conﬁrmed by colony PCR and Sanger sequencing.
P. falciparum transfection. Seventy-ﬁve micrograms of each plasmid
(pTEOE110:PfHAD1 and pHTH) was combined, precipitated and resuspended in
400 ml Cytomix (120mM KCl, 0.15mM CaCl2, 2mM EGTA, 5mM MgCl2, 10mM
K2HPO4, 25mM HEPES, pH 7.6).
A 4-ml culture of FSMR strain AM1 was synchronized by treatment with 5%
sorbitol to obtain ring-stage parasites at44% parasitemia. Cells were washed with
Cytomix and resuspended in 400ml DNA/Cytomix solution. Cells were
electroporated using a Biorad GenePulser II electroporator set to 950 mF
capacitance and 0.31 kV. Transfected cells were washed with media and returned to
the previously described culture conditions. Culture media was replaced daily for
one week. Cultures were maintained under selection with 5 nM WR92210 (Jacobus
Pharmaceutical Co.) beginning 48 h post transfection. Parasite growth was
monitored by microscopy. Successful transfectants were cloned by limiting
dilution. The resulting strain was veriﬁed by microscopy, western blot and
sequencing of the endogenous PfHAD1 locus.
Generation of PfHAD1 polyclonal antisera. PfHAD1 rabbit polyclonal antisera
was produced by Cocalico Biologicals (Reamston, PA) using their standard pro-
tocol. Puriﬁed recombinant 6XHis-PfHAD1 was used as an antigen. Titermax was
used as an adjuvant.
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Immunoblotting. P. falciparum cells were obtained by treatment of infected ery-
throcytes with 0.1% saponin. Lysates were separated on a polyacrylamide gel and
transferred to polyvinylidene ﬂuoride membrane. For the detection of PfHAD1, the
membrane was blocked and probed with 1:20,000 anti-PfHAD1 polyclonal antisera
(Cocalico Biologicals), followed by 1:20,000 HRP-conjugated goat anti-rabbit IgG
polyclonal antibody (Life Technologies). The membrane was stripped by treatment
with 200mM glycine, 0.1% sodium dodecyl sulphate, 1% Tween-20 (pH 2.2) and
reprobed with 1:5,000 anti-heat shock protein 70 antibody (Agrisera) as a loading
control.
Enzymatic assays. All assays were performed in clear 96-well half-area plates
using a FLUOstar Omega microplate reader (BMG Labtech) at 37 C. Reaction
rates were determined using GraphPad Prism software.
Phosphatase activity was measured using the substrate pNPP (New England
Biolabs). Reactions were performed in 50 ml volumes with 10mM pNPP, 50mM
Tris HCl (pH 7.5), 5mM MgCl2 and 0.5mM MnCl2. Reactions contained 2 mg
puriﬁed recombinant enzyme. Para-nitrophenyl production was quantiﬁed by
absorbance at 405 nm.
Enzyme activity against phosphorylated sugar substrates was measured using
the Enzchek Phosphate Assay Kit (Life Technologies) according to supplier
instructions. Each assay contained 200 ng recombinant puriﬁed enzyme and 1mM
substrate. Substrates were purchased from Sigma-Aldrich, except for DOXP and
MEP (Echelon Biosciences), fructose 1-phosphate (Santa Cruz Biotechnology) and
FSM (Life Technologies).
For the determination of kinetic parameters, assays were performed using 50 ng
6XHis-PfHAD1 and 0.03–12mM substrate. Data were ﬁt to Michaelis–Menten
curves using GraphPad Prism software.
Microscopy. For immunoﬂuorescence microscopy, cells at B10% parasitemia
were ﬁxed in 4% paraformaldehyde in PBS. Fixed cells were washed with 50mM
ammonium chloride, permeabilized by treatment with 0.075% NP-40 in PBS and
blocked using 2% bovine serum albumin. Cells were incubated with the following
antibody dilutions: 1:10,000 rabbit polyclonal anti-PfHAD1 (described above) and
1:1,000 mouse monoclonal anti-GFP (Life Technologies #A11120) for the detection
of GFP in the ACPL-GFP strain (MRA-568). Hoechst 33258 (Life Technologies)
was used as a nuclear counterstain. Secondary antibodies used were 1:200 dilutions
of Alexa Fluor 568 goat anti-rabbit IgG (Life Technologies #A11011) and Alexa
Fluor 488 goat anti-mouse IgG (Life Technologies #A11029). Images were obtained
on an Olympus Fluoview FV1000 confocal microscope.
For imaging of live cells, cells were stained with 10 ng ml 1 Hoechst 33258 for
10min and mounted under coverslips on polysine adhesion slides. Cells were
visualized on an Olympus BH8 microscope at room temperature for no longer than
15min.
For all microscopy, minimal adjustments in brightness and contrast were
applied equally to all images.
Sample preparation for mass spectrometry analysis. P. falciparum were cul-
tured in 75ml volumes in 150 25mm tissue culture dishes at 4% haematocrit
until 46% parasitemia was reached. Cultures were synchronized by one to two
treatments with 5% sorbitol until48% parasitemia and475% of parasites were in
ring-stage growth. Once these criteria were met, 75ml cultures were split into
3 25ml samples. Ring-stage cultures were then treated þ / 5 mM FSM (Life
Technologies) for either 0 or 10 h. At each time point, parasite-infected ery-
throcytes were lysed with 0.1% saponin, the parasite pellets washed with PBS and
the pellets stored at  80 C until extraction. Samples were extracted and analysed
by liquid chromatography-mass spectrometry as previously described8. Brieﬂy,
samples were extracted in chloroform, methanol and acetonitrile (2:1:1, v/v/v) and
homogenized. Water was added and the sample was homogenized again. The polar
phase was separated by centrifugation, lyophilized and resuspended in water for
analysis.
Quantitative PCR of PfDXS and PfDXR transcripts. Infected erythrocytes were
lysed by treatment with 0.1% saponin. Parasite pellets were stored at  80 C until
extraction. Total RNA was isolated using the Ambion Purelink RNA Mini kit (Life
Technologies) according to the supplier’s instructions. After the ﬁrst wash step,
samples underwent an on-column DNase treatment (Qiagen) for 30min. RNA was
eluted in RNase-free water, quantiﬁed and stored at  80 C until further use. At
least 100 ng of RNA was used to synthesize cDNA using the Quantitect Reverse
Transcription kit (Qiagen), according to the supplier’s instructions.
Ampliﬁcation of cDNA was performed using an Applied Biosystems Fast RT
PCR System and Applied Biosystems Fast SYBR Green PCR Master Mix (Life
Technologies). PfDXS (PlasmoDB ID PF3D7_1337200) was ampliﬁed using the
following primers: 50-AACGTGGATAAAGTACACATTGC-30 and 50-TGATATA
CTTACGGCATTTGTTGG-30 and PfDXR (PlasmoDB ID PF3D7_1467300) was
ampliﬁed using the following primers; 50- ACATGGCCTGATAGAATAAAA
ACA-30 and 50- TTCATTTGACGCATTTAGTACAGTT-30 (Sigma-Aldrich). The
gene encoding beta tubulin (PF3D7_1008700) was used as a control and was
ampliﬁed using the following primers: 50-ATCCCATTCCCACGTTTACATT-30
and 50-TCCTTTGTGGACATTCTTCCTC-30 (Euroﬁns MWG Operon). Standard
curves were used to verify primer efﬁciency (r2 40.97, E 480%). In addition to
SYBR Master Mix, reactions contained 10 ng cDNA and 300 nM of each primer.
All reactions were performed in MicroAmp Fast Optical 96-well plates (Life
Technologies).
Thermocycling parameters were as follows: 95 C for 30 s, 40 cycles of 95 C for
3 s and 60 C for 30 s. Agarose gel electrophoresis, as well as melt-curve analysis,
with temperatures ranging from 60 to 95 C, conﬁrms production of a single
product from each primer pair. Controls lacking either reverse transcriptase or
template produced no signiﬁcant signals. Ct values were generated using 7500 Fast
System software (Applied Biosystems).
Relative PfDXS and PfDXR expression levels were calculated using the DDCt
method. DCt values were calculated by subtracting the Ct of the reference gene
(beta tubulin) from the target gene (PfDXS or PfDXR). DDCt values were then
calculated by normalizing to the DCt of the parental sample. Relative expression
changes were calculated as 2DDCt.
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